Loading patent…
AssigneeEirgen Pharma Ltd.
InventorsPhillip FROST, Antonio CRUZ, John K. CHOE, Jane H. HSIAO
Estimating the term…
The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the flavone apigenin to support cognitive health in a subject that takes the product or combination product. The invention relates to compositions comprising scyllo-inositol alone or in combination with other agents including but not limited to a flavone or other substance that upregulates or prevents the downregulation of aquaporin 4 channels. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system.
A combination of (i) a first compound selected from an inositol or a pharmaceutically acceptable isomer or salt thereof and (ii) a second compound selected from a molecule that upregulates aquaporin 4.
4-5. (canceled)
A dosage form comprising a combination of (i) a first compound selected from an inositol or a pharmaceutically acceptable isomer or salt thereof and (ii) a second compound selected from a flavone.
A method of treating a subject having an MMSE score in the range of 22-26 with a pharmaceutically effective amount of scyllo-inositol.
17-30. (canceled)
A method of supporting cognitive health comprising the administration of a nutraceutically effective amount of a composition comprising scyllo-inositol and apigenin.
(canceled)
Dependencies are inferred from the claim text.